{"id":"a-101-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site pain or burning"},{"rate":null,"effect":"Hyperpigmentation"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A-101 contains a high-concentration hydrogen peroxide formulation designed to selectively destroy targeted skin tissue. When applied topically, it creates a controlled chemical burn that leads to necrosis and sloughing of the lesion, allowing healthy skin to regenerate. The mechanism is distinct from traditional keratolytic agents and works through direct cytotoxic effects on the lesion tissue.","oneSentence":"A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:24.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seborrheic keratosis"},{"name":"Common warts"},{"name":"Molluscum contagiosum"}]},"trialDetails":[{"nctId":"NCT05720819","phase":"NA","title":"Biofeedback-VR for Treatment of Chronic Migraine","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-09-09","conditions":"Chronic Migraine, Behavioral Treatment, Biofeedback","enrollment":50},{"nctId":"NCT02260180","phase":"PHASE2","title":"Study of A-101 for the Treatment of Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2014-10","conditions":"Seborrheic Keratosis","enrollment":119},{"nctId":"NCT03812510","phase":"PHASE3","title":"Safety Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2019-02-07","conditions":"Common Wart","enrollment":426},{"nctId":"NCT03691831","phase":"PHASE3","title":"A Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-13","conditions":"Common Wart","enrollment":502},{"nctId":"NCT03687372","phase":"PHASE3","title":"Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-17","conditions":"Common Wart","enrollment":503},{"nctId":"NCT03224598","phase":"PHASE2","title":"A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-06-26","conditions":"Dermatosis Papulosa Nigra","enrollment":39},{"nctId":"NCT03487588","phase":"PHASE4","title":"An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-03-21","conditions":"Seborrheic Keratosis","enrollment":41},{"nctId":"NCT03148691","phase":"PHASE2","title":"A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-05-17","conditions":"Seborrheic Keratosis","enrollment":253},{"nctId":"NCT03210337","phase":"PHASE2","title":"A Phase2 of A-101 Topical Solution in Subjects With Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-08-01","conditions":"Common Wart","enrollment":157},{"nctId":"NCT03278028","phase":"PHASE2","title":"A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-07-13","conditions":"Common Wart","enrollment":159},{"nctId":"NCT02160626","phase":"PHASE2","title":"Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2014-06","conditions":"Seborrheic Keratosis","enrollment":172},{"nctId":"NCT01986920","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2013-10-22","conditions":"Seborrheic Keratosis (SK)","enrollment":35},{"nctId":"NCT02669862","phase":"PHASE2","title":"A Study of A-101 Solution in Subjects With Common Warts.","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2015-12-21","conditions":"Common Warts","enrollment":98},{"nctId":"NCT02667288","phase":"PHASE3","title":"An Open-Label Safety Study of A-101 Solution","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":147},{"nctId":"NCT02667275","phase":"PHASE3","title":"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":487},{"nctId":"NCT02667236","phase":"PHASE3","title":"A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["hydrogen peroxide 45%"],"phase":"phase_3","status":"active","brandName":"A-101 Solution","genericName":"A-101 Solution","companyName":"Aclaris Therapeutics, Inc.","companyId":"aclaris-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism. Used for Seborrheic keratosis, Common warts, Molluscum contagiosum.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}